Literature DB >> 32249602

IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?

Xuefeng Xu1, Jinglan Zhang1, Huaping Dai2,3.   

Abstract

IMPACT STATEMENT: We suggest a novel modality in terms of IL-25/IL-33/TSLP's pro-fibrotic role in IPF. First, IL-25/IL-33/TSLP fully activates (myo)fibroblasts in fibroblastic foci (FF) in a paracrine-dependent manner. (IL-25/IL-33/TSLP)+alveolar epithelial cells-(IL-25R/IL-33R/TSLPR)+ (myo)fibroblasts axis may contribute greatly to the abnormal epithelial-mesenchymal crosstalk and lung fibrosis. Second, IL-25/IL-33/TSLP causes significant injury and phenotypic changes of alveolar epithelial cells in an autocrine-dependent manner. By acting directly on the two most important cells in the fibrotic process, i.e. alveolar epithelial cells and (myo)fibroblasts, we support the notion that biological therapies targeting IL-25/IL-33/TSLP will shed new light on the cure of IPF patients.

Entities:  

Keywords:  Epithelial-mesenchymal crosstalk; IL-25/IL-33/TSLP; fibroblastic foci; idiopathic pulmonary fibrosis

Mesh：

Substances：

Year:  2020        PMID： 32249602      PMCID： PMC7268928          DOI： 10.1177/1535370220915428

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


  32 in total

1.  IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis.

Authors:  Hyun-Woo Shin; Dong-Kyu Kim; Min-Hyun Park; Kyoung Mi Eun; Mingyu Lee; Daeho So; Il Gyu Kong; Ji-Hun Mo; Min-Suk Yang; Hong Ryul Jin; Jong-Wan Park; Dae Woo Kim
Journal:  J Allergy Clin Immunol       Date:  2015-02-25       Impact factor: 10.793

Review 2.  Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul W Noble; Robert J Homer
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08       Impact factor: 6.914

Review 3.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 4.  Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications.

Authors:  Paolo Spagnolo; Giulio Rossi; Alberto Cavazza
Journal:  Expert Rev Clin Immunol       Date:  2014-06-23       Impact factor: 4.473

Review 5.  Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Fernando J Martinez
Journal:  N Engl J Med       Date:  2018-05-10       Impact factor: 91.245

6.  Interleukin-33 potentiates bleomycin-induced lung injury.

Authors:  Irina G Luzina; Pavel Kopach; Virginia Lockatell; Phillip H Kang; Ashish Nagarsekar; Allen P Burke; Jeffrey D Hasday; Nevins W Todd; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

Review 7.  Epithelial Injury and Dysfunction in the Pathogenesis of Idiopathic PulmonaryFibrosis.

Authors:  Nichelle I Winters; Ankita Burman; Jonathan A Kropski; Timothy S Blackwell
Journal:  Am J Med Sci       Date:  2019-01-22       Impact factor: 2.378

8.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

9.  ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis.

Authors:  Shunji Tajima; Masashi Bando; Shoji Ohno; Yukihiko Sugiyama; Katsuhisa Oshikawa; Shin-ichi Tominaga; Kouichi Itoh; Toshinori Takada; Eiichi Suzuki; Fumitake Gejyo
Journal:  Exp Lung Res       Date:  2007-03       Impact factor: 2.459

10.  Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease.

Authors:  Arnab Datta; Robert Alexander; Michal G Sulikowski; Andrew G Nicholson; Toby M Maher; Chris J Scotton; Rachel C Chambers
Journal:  J Immunol       Date:  2013-09-30       Impact factor: 5.422
View more
  2 in total

1.  Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.

Authors:  Katarzyna Kotfis; Igor Karolak; Kacper Lechowicz; Małgorzata Zegan-Barańska; Agnieszka Pikulska; Paulina Niedźwiedzka-Rystwej; Miłosz Kawa; Jerzy Sieńko; Aleksandra Szylińska; Magda Wiśniewska
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-05

Review 2.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.